Third-line Therapy for metastatic Renal cell carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
机构：
[1] MeckEvidence Geschaftsstelle AUO, D-17252 Schwarz, Germany
来源：
ONKOLOGE | 2011年 / 17卷 / 12期
关键词：
D O I：
10.1007/s00761-011-2173-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1161 / 1162
页数：2
相关论文
共 50 条
  • [1] Third-line Therapy for metastatic Renal Cell Carcinoma
    Rexer, H.
    [J]. UROLOGE, 2011, 50 (10): : 1319 - 1321
  • [2] Third-line dovitinib in metastatic renal cell carcinoma
    Schmidinger, Manuela
    [J]. LANCET ONCOLOGY, 2014, 15 (03): : 245 - 246
  • [3] Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Wells, J. Connor
    Stukalin, Igor
    Norton, Craig
    Srinivas, Sandy
    Lee, Jae Lyun
    Donskov, Frede
    Bjarnason, Georg A.
    Yamamoto, Haru
    Beuselinck, Benoit
    Rini, Brian I.
    Knox, Jennifer J.
    Agarwal, Neeraj
    Ernst, D. Scott
    Pal, Sumanta K.
    Wood, Lori A.
    Bamias, Aristotelis
    Alva, Ajjai S.
    Kanesvaran, Ravindran
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    [J]. EUROPEAN UROLOGY, 2017, 71 (02) : 204 - 209
  • [4] Third-line treatment in metastatic renal cell carcinoma and bone metastases
    Heng, Daniel Y. C.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (7-8): : 268 - 268
  • [5] Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
    Roberto, Michela
    Bassanelli, Maria
    Iannicelli, Elsa
    Giacinti, Silvana
    D'Antonio, Chiara
    Aschelter, Anna Maria
    Marchetti, Paolo
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [6] Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma
    Fujita, Tetsuo
    Hirayama, Takahiro
    Nishi, Morihiro
    Matsumoto, Kazumasa
    Yoshida, Kazunari
    Iwamura, Masatsugu
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (05) : 505 - 510
  • [7] Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Federico, Piera
    Rescigno, Pasquale
    Milella, Michele
    Ortega, Cinzia
    Aieta, Michele
    D'Aniello, Carmine
    Longo, Nicola
    Felici, Alessandra
    Ruggeri, Enzo Maria
    Palmieri, Giovannella
    Imbimbo, Ciro
    Aglietta, Massimo
    De Placido, Sabino
    Mirone, Vincenzo
    [J]. EUROPEAN UROLOGY, 2010, 58 (06) : 906 - 911
  • [8] ACTIVITY OF SUNITINIB AS THIRD-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) (JAPAN)
    Nozawa, M.
    Mochida, Y.
    Nishigaki, K.
    Nagae, S.
    Uemura, H.
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : I11 - I11
  • [9] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    [J]. AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [10] Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
    Heng, Daniel Yick Chin
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Yamamoto, Haru
    Ernst, D. Scott
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345